Online inquiry

IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4604MR)

This product GTTS-WQ4604MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014218.3; NM_014219.2; NM_015868.3; NM_014512.1; KIR2DS2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3802; 3803; 3804; 3806; 100132285
UniProt ID P43626; P43627; P43628; Q14954; P43631
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4604MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8968MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ14744MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ2624MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ9044MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ6843MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ7713MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ1119MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ11401MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-575
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW